Literature DB >> 16799256

Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase.

Mizuo Miyazaki1, Shinji Takai.   

Abstract

It had been believed that angiotensin II (Ang II) was produced by the renin-angiotensin system (RAS), which was established in the 1950's. After a while, people realized that the multiple functions of Ang II could not be explained by the conventional RAS. We have tried to determine the existence of the tissue Ang II generating system. At first, we found that vascular angiotensin-converting enzyme (ACE) was increased to generate local Ang II in the vessels of hypertension and was enhanced in lipid-loaded atherosclerosis, to respond to ACE inhibitor or Ang II antagonist (ARB). In both cases, Ang II production in vessels was independent from the systemic RAS that was estimated by the plasma renin activity. On the way to clarifying the roles of the vascular ACE, we noticed that vascular Ang II production was not completely suppressed by ACE inhibitor alone. This evidence led us to discover different types of chymase as a new Ang II producing enzyme. Now, we have obtained a strategy to distinguish the Ang II one by one, that is, circulating RAS derived, tissue ACE derived, and chymase derived. It is essential to understand not only the intracellular mechanisms of Ang II but also the process of Ang II productions in each disease to show accurate indications of the effectiveness of ACE inhibitor, ARB, and chymase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799256     DOI: 10.1254/jphs.cpj06008x

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  40 in total

Review 1.  The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease.

Authors:  Ana Cristina Simões E Silva; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2011-09-23       Impact factor: 3.714

Review 2.  Potential targets for intervention in radiation-induced heart disease.

Authors:  M Boerma; M Hauer-Jensen
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

Review 3.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

Review 4.  The renin-angiotensin system and prevention of age-related functional decline: where are we now?

Authors:  Corey B Simon; Brittany Lee-McMullen; Dane Phelan; Janine Gilkes; Christy S Carter; Thomas W Buford
Journal:  Age (Dordr)       Date:  2015-02-09

5.  ACE2/Ang-(1-7)/Mas axis stimulates vascular repair-relevant functions of CD34+ cells.

Authors:  Neha Singh; Shrinidh Joshi; Lirong Guo; Matthew B Baker; Yan Li; Ronald K Castellano; Mohan K Raizada; Yagna P R Jarajapu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

Review 6.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

7.  Enhanced vascular chymase-dependent conversion of endothelin in the diabetic kidney.

Authors:  Lisa M Harrison-Bernard; Lawrence de Garavilla; Benjamin J Bivona
Journal:  Ochsner J       Date:  2013

8.  Alpha-1 antitrypsin, a diagnostic and prognostic marker of vernal keratoconjunctivitis.

Authors:  Akif Ahsan; Khushtar A Salman; Sana Alam; Anwar H Siddiqui; Syed Shariq Naeem; Aquil Ahmad; Iqbal M Khan
Journal:  J Clin Diagn Res       Date:  2014-05-15

Review 9.  The intracellular renin-angiotensin system in the heart.

Authors:  Rajesh Kumar; Vivek P Singh; Kenneth M Baker
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

Review 10.  Alveolar hypoxia, alveolar macrophages, and systemic inflammation.

Authors:  Jie Chao; John G Wood; Norberto C Gonzalez
Journal:  Respir Res       Date:  2009-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.